The key news surrounding Quest Diagnostics (DGX) encapsulates a mix of strategic acquisitions, financial performance, dividend declarations, executive appointments, and market performance insights. Quest has made a strategic acquisition of select laboratory assets from Fresenius Medical Care and other relevant entities enhancing their diagnostic services. Regulatory appointments took center stage with hiring of Adrienne Brott as SVP and Chief Quality and Regulatory Affairs Officer. Other notable acquisitions include LifeLabs and PathAI Diagnostics. Quest has reported its Q4 2024 earnings with strong performance, and hiked its quarterly dividend by 6.7%. Their stock saw a steep rise of 38% within a year, instigating a bullish outlook on Wall Street. An impending Investor Day is scheduled for March 19, 2025. The company has also launched personalized health coaching services. Their yearly results and stock performance indicate the positive momentum, with them reaching an all-time high at $176.53. They are committed to innovation and quality, reflected in their initiatives such as introduction of self-collection for infection testing and launching bird flu tests.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Fri, 14 Mar 2025 09:08:48 GMT - Rating 7 - Innovation 4 - Information 9 - Rumor 3
